Back to News
Market Impact: 0.1
Lilly Highlights Immune And Metabolic Effects Of Taltz Plus Zepbound
Source: Nasdaq
Healthcare & Biotech
Eli Lilly reported new exploratory Phase 3b data from the TOGETHER-PsO study evaluating Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with psoriasis and obesity or overweight. The article excerpt provides no study results or numerical outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- We’re still figuring out the side effects of GLP-1 weight-loss drugs
- Jim Cramer's top 10 things to watch in the stock market Friday
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down